Biotechnology development company Fapon Biotech Inc reported on Monday that Mucormycosis (black fungus) is a devastating infection that continues to rise in India during the COVID-19 pandemic, with more than 57,150 cases and a mortality of 54% in the country.
In addition to the high prevalence of diabetes in India, COVID-17 infected countries Pakistan, Russia, Nepal, Chile and Brazil, among others, have described the same problem and in areas with high rates of infection by diabetes and COVID-19 there should be alarm.
The company is calling for academic and industry partners in the development of mucormycosis diagnostic tests to share the capabilities of early stage raw material development platforms and reagent application platforms in the early stage. final phase.
Fapon Biotech supplies reagent raw materials for COVID-19 detection, with proven experience in helping partners to launch accredited reagents for COVID-19 in a short time.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval